Search Bar & Filters
Found 21 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are investigating the impact of anti-inflammatory nutrition on the success of non-surgical periodontal treatment in people with periodontitis who follow a pro-inflammatory diet. The study aims to assess changes in specific biomarkers found in gingival crevicular fluid and blood serum, as well as clinical periodontal health parameters. This observational study will include 100 adults aged 20 to 65 years who have periodontitis and a dietary inflammatory index greater than zero. Participants will be divided into four groups based on diet inflammatory scores and whether they receive anti-inflammatory nutrition education. All will undergo non-surgical periodontal treatment. Two groups Q3-1 and Q4-1 will receive both the periodontal treatment and nutrition education, while the other two groups Q3-2 and Q4-2 will receive only the periodontal treatment. Samples and measurements will be collected at baseline, 1.5 months, and 3 months after treatment to evaluate changes. Throughout the study, participants will have clinical periodontal assessments and provide gingival fluid and blood samples to measure levels of inflammatory and oxidative stress markers like interleukins, tumor necrosis factor, total oxidant and antioxidant status, and C-reactive protein. Researchers will track periodontal pocket depth and clinical attachment loss over time. The study will last about 3 months after treatment, with multiple follow-up visits to monitor changes and treatment outcomes.
Actively Recruiting
Healthy Volunteer
This research aims to assess the effect of 10 Hz alpha-band binaural beats embedded in rain sound on reducing anxiety, stabilizing vital signs, and aiding recovery in adults undergoing impacted third molar wisdom tooth extraction. The study targets healthy adults aged 18 to 45 who experience stress during oral surgery due to anxiety and loud equipment noises. By exploring this non-invasive sound therapy, researchers seek alternatives to medication that may help manage surgical stress and pain. Participants are randomly divided into three groups one listens to the 10 Hz binaural beats with rain sounds through active noise-cancelling ANC headphones during surgery another hears only rain sounds via ANC headphones and the last group wears ANC headphones with no audio, using noise cancellation alone. Surgical procedures follow a standardized approach, and the headphones are worn only during the surgery. Throughout the study, participants complete anxiety questionnaires before surgery and have heart rate, blood pressure, and oxygen levels monitored at key surgical moments. After surgery, stress and discomfort scales are recorded, and participants keep a 7-day diary of pain and pain medication use. These measurements help compare the calming effects and recovery outcomes among the groups. The entire study concludes by the end of 2026.
Actively Recruiting
Healthy Volunteer
Researchers are investigating peri-implant diseases such as peri-implantitis and peri-implant mucositis, which are common biological complications affecting dental implants despite advances in implant technology. The study focuses on measuring levels of vitamin D metabolite 25OHD3 and the antimicrobial peptide LL-37 in peri-implant sulcus fluid PIOS and explores their relationship with inflammatory markers IL-6, IL-10, and MMP-8, along with clinical parameters related to implant health. This observational study aims to better understand these biomarkers and their role in disease processes around dental implants. Participants will be grouped based on peri-implant health status healthy, peri-implant mucositis, and peri-implantitis. Clinical evaluations include measuring probing pocket depth, clinical attachment level, bleeding, plaque, gingival indices, keratinized and attached gingival tissue amounts. Samples of peri-implant sulcus fluid and blood serum will be collected for laboratory analysis of vitamin D and LL-37 levels. The study does not involve interventional treatments but collects data to assess biomarker correlations. During the study, participants will undergo clinical dental assessments and provide fluid and blood samples at baseline. Researchers will analyze these samples alongside clinical data to evaluate the connections between biomarker levels and peri-implant disease status. The primary outcomes measured are probing pocket depth and clinical attachment level, while secondary outcomes include levels of 25OHD3 and LL-37. Participation will last through the baseline assessment with no active treatment involved, aiming to improve early diagnosis and potential treatment strategies for peri-implant diseases.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the relationship between hyperuricemia, a condition with high serum uric acid levels, and periodontitis, a chronic gum disease causing inflammation and bone loss. The study aims to understand how hyperuricemia may influence periodontitis through inflammation, oxidative stress, and bone metabolism. This observational research includes 80 adults aged 18 to 65, divided into four groups based on gum health and uric acid levels. Participants will have their periodontal health evaluated using clinical measures such as probing pocket depth and clinical attachment loss. Gingival crevicular fluid and blood serum samples will be collected to analyze markers related to inflammation, oxidative stress, and bone metabolism, including various interleukins and nuclear factor kappa B ligand. The study groups include those with and without periodontitis and hyperuricemia. Throughout the study, participants will undergo thorough assessments of periodontal parameters alongside laboratory tests on collected samples. The main outcomes measured are periodontal pocket depth and clinical attachment loss at baseline, with additional analysis of inflammatory markers. The study is conducted by Recep Tayyip Erdogan University Training and Research Hospital and is expected to complete by October 2026.
1-10 of 21
1